Search Results
237 items found for " Ovarian Cancer"
Posts (113)
- Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid...
September 2022 Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid cancer patients for pain management. Although increasing evidence has suggested the direct role of fentanyl on cancer, little is known on the effect of fentanyl on ovarian cancer cells. Methods Proliferation, migration and apoptosis assays were performed in ovarian cancer cells after fentanyl
- Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation..
September 2022 Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Here, we report that the Ovarian Cancer G-Protein Coupled Receptor1 (OGR1 or GPR68) has dual roles in
- 📰 GPCR Weekly News, June 17 to 23, 2024
GPCRs in Oncology and Immunology Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer cancer cells by targeting PAR-1 G protein-coupled receptors related to autoimmunity in postural orthostatic cancer prognosis GprC of the nematode-trapping fungus Arthrobotrys flagrans activates mitochondria and reprograms fungal cells for nematode hunting Role and recent progress of P2Y12 receptor in cancer development immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision Structural and Molecular
Other Pages (124)
- Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer
Cancer Published date April 18, 2024 Abstract "Ovarian cancer ranks as a leading cause of mortality UCA1 expression inversely correlates with survival outcomes and therapy response in ovarian cancer clinical cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis in ovarian cancer. Carcinoma , Let-7 miRNAs , Oncogenic Pathways , Ovarian Cancer , Therapy Resistance , UCA1 , lncRNA
- Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design
FTs, the origin of ovarian cancer, are known to express genes of serous tubal intraepithelial carcinoma PAR2 expression in FTs may serve as an early prediction sensor for ovarian cancer. We show now that knocking down Par2 inhibits ovarian cancer peritoneal dissemination in vivo, pointing The potent inhibitory function of Pc(4-4) is demonstrated via inhibition of ovarian cancer peritoneal serve as a powerful medicament in STICs and ovarian cancer.
- Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation
cancer nanomedicines: from RNA sequencing data analysis to in vitro validation Published date July 27 , 2024 Abstract "Genetic heterogeneity in ovarian cancer indicates the need for personalised treatment To address the genetic heterogeneity of ovarian cancer, a future personalised approach could include cancer tissues. Subsequently, primary ovarian cancer cells derived from ascites and ovarian cancer cell lines were used